Contents

Search

gilteritinib (Xospata)

Indications: - acute myeloid leukemia (AML), FLT3 mutation positive - for use in combination with standard cytarabine & daunorubicin induction & cytarabine consolidation Dosage: - 80 mg PO QD (40-120 mg) on days 4-17 of each 28 day cycle Adverse effects: - febrile neutropenia 65.3% - thrombocytopenia 20.4% Mechanism of action: - inhibits FLT3 receptor tyrosine kinase - also inhibits anaplastic lymphoma kinase (ALK, CD246) [2]

Interactions

drug adverse effects of tyrosine kinase inhibitor(s)

General

antineoplastic agent (chemotherapeutic agent) tyrosine kinase inhibitor

Database Correlations

PUBCHEM correlations

References

  1. O'Neil A, Klil-Drori AJ. AML: FLT3 Inhibitor Shows 'Robust' Activity as Frontline Therapy - Overall response rate 100% in patients with FLT3- mutated disease in early research. MedPage Today. Jan 17, 2018 https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/70559
  2. PubChem: 49803313
  3. HIGHLIGHTS OF PRESCRIBING INFORMATION XOSPATA (gilteritinib) tablets, for oral use https://astellas.us/docs/xospata.pdf